Stockscreener 앱 받기
1.38
1.47%
0.02
시간 외 거래:
1.38
Coherus Oncology Inc 주식(CHRS)의 최신 뉴스
Coherus Oncology, Inc. 8-K SEC Filing June 12, 2026 – Entity Information, Common Stock, NASDAQ, and Exhibit Letter from Ernst & Young LLP 18205556 – Minichart - Minichart
Coherus Oncology appoints PwC as new auditor, replaces Ernst & Young - Investing.com
[8-K] Coherus Oncology, Inc. Reports Material Event - Stock Titan
Coherus Oncology (CHRS) director receives 30K RSUs and 60K stock option grant - Stock Titan
[Form 4] Coherus Oncology, Inc. Insider Trading Activity - Stock Titan
CHRS: Immuno-oncology pipeline advances with key data and global deals expected in 6–18 months - TradingView
CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill
CHRS Q1 2026 Earnings: Narrower-Than-Expected Loss Despite Negative Stock ReactionEarnings Surprise Report - newsline.com
Coherus Oncology (CHRS) CFO receives repriced $1.59 stock options, cancels higher-strike grants - Stock Titan
Coherus (NASDAQ: CHRS) reprices 3.2M CEO stock options to $1.59 - Stock Titan
Coherus Biosciences Announces 2026 Stockholder Meeting Results - The Globe and Mail
Coherus Oncology, Inc. 8-K SEC Filing: Company Details, Stock Information, and Compliance Disclosures (May 27, 2026) - Minichart
Coherus Oncology shareholders approve director elections and equity plan changes - Investing.com Canada
Coherus Oncology shareholders approve director elections and equity plan changes By Investing.com - Investing.com South Africa
Coherus Oncology (CHRS) shareholders approve equity plan changes and option repricing - Stock Titan
Coherus Oncology (CHRS) reports Q1 loss, lags revenue estimates - MSN
TD Cowen Maintains Coherus Oncology(CHRS.US) With Buy Rating - Moomoo
CHRS: All proposals passed except the stock option price reduction, which was adjourned - TradingView
CHRS: Directors and key proposals were approved; stock option vote adjourned to May 29, 2026 - TradingView
Coherus Oncology Inc. (CHRS) Rises 2.55%: Key Levels to Watch After Support HoldETF AUM Growth - newsline.com
Coherus Oncology (CHRS) Holds Above Support After Modest GainNAAIM Exposure - newsline.com
Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncolog - AD HOC NEWS
Coherus Oncology Q1 earnings call highlights - MSN
What Does The Future Hold For Coherus Oncology, Inc. (NASDAQ:CHRS)? These Analysts Have Been Cutting Their Estimates - 富途牛牛
Coherus BioSciences stock (US19247A1007): earnings reset and oncology focus after Humira biosimilar - AD HOC NEWS
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook By Investing.com - Investing.com Australia
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook - Investing.com UK
Timothy Youngquist Trust amends 13G; holds 12.75M CHRS (NASDAQ: CHRS) - Stock Titan
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill
What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today - Yahoo Finance
Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives - Sahm
CHRS SEC FilingsCoherus 10-K, 10-Q, 8-K Forms - Stock Titan
Maxim Group Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Coherus Oncology, Inc. (NASDAQ:CHRS) Q1 2026 Earnings Call Transcript - Insider Monkey
Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS) - Seeking Alpha
Number of shareholders of Coherus Oncology, Inc. – MUN:8C5 - TradingView
Kura Oncology Q1 Earnings Call Highlights - inkl
Coherus Oncology (CHRS) Reports Q1 Earnings and Updates on LOQTO - GuruFocus
CHRS: Coherus Oncology, Inc.Interactive Chart - Zacks Investment Research
Coherus Oncology (CHRS) Reports Q1 2026 Earnings and Future Proj - GuruFocus
Coherus targets $15M quarterly LOQTORZI sales in 2026 while advancing midyear tagmokitug and casdozokitug readouts - MSN
Coherus Oncology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: St - GuruFocus
Coherus Oncology Q1 2026 Earnings Call Transcript - MarketBeat
1.27%
1.43%
자본화:
|
볼륨(24시간):